La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lexicon Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mike Exton

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	17yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Apr 25

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Jan 04

AMMINISTRATORE DELEGATO

Mike Exton (54 yo)

less than a year

Mandato

Dr. Michael Exton, also known as Mike, Ph D is CEO & Director of Lexicon Pharmaceuticals, Inc. from July 08, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey Wade	President & COO	2.8yrs	US$1.96m	0.090% $ 557.7k
Brian Crum	Senior VP	14.3yrs	US$1.42m	0.049% $ 305.3k
Alan Main	Executive Vice President of Innovation & Chemical Sciences	23.1yrs	US$1.39m	0.071% $ 439.8k
Craig Granowitz	Senior VP & Chief Medical Officer	3yrs	US$1.53m	0.013% $ 81.9k
Michael Exton	CEO & Director	less than a year	Nessun dato	Nessun dato
Kristen Alexander	Vice President of Finance & Accounting	2.9yrs	Nessun dato	0.013% $ 82.2k
Lisa DeFrancesco	Head of Investor Relations & Corporate Strategy	less than a year	Nessun dato	Nessun dato
Dixon Terry	Vice President of Compliance	2.5yrs	Nessun dato	Nessun dato
Carrie Siragusa	Vice President of Marketing	1.2yrs	Nessun dato	Nessun dato
Desiree Gendron	Vice President of Sales & Training	no data	Nessun dato	Nessun dato
Wendy McDermott	Vice President of Human Resources	2.6yrs	Nessun dato	0.015% $ 90.7k
Kenneth Kassler-Taub	Senior Vice President of Regulatory Affairs & Quality Assurance	2.8yrs	US$1.48m	0.045% $ 279.8k

2.8yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di LXRX è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Exton	CEO & Director	less than a year	Nessun dato	Nessun dato
Raymond Debbane	Independent Chairman of the Board	17yrs	US$127.82k	0.37% $ 2.3m
Samuel Barker	Independent Director	24.4yrs	US$117.46k	0.024% $ 150.8k
Philippe Amouyal	Independent Director	17yrs	US$100.52k	0.069% $ 427.2k
Robert Lefkowitz	Independent Director	23.5yrs	US$94.96k	0.013% $ 83.2k
Christopher Sobecki	Independent Director	17yrs	US$89.96k	0.046% $ 287.3k
Judith Swain	Independent Director	16.9yrs	US$104.96k	0.013% $ 83.2k
Alan Nies	Chairman of Medical Advisory Board	21.4yrs	US$82.87k	0.011% $ 70.6k
Diane Sullivan	Independent Director	1.1yrs	US$176.42k	Nessun dato

17.0yrs

Durata media

69yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LXRX è composto da personale esperto e esperto (durata media dell'incarico 17 anni).

Lexicon Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

CEO & Director exercised options and sold US$161k worth of stock

Recent updates

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $62.204233 million.

Lexicon Pharmaceuticals, Inc. Announces Fda Approval of Inpefa™ (Sotagliflozin) for Treatment of Heart Failure

Consensus revenue estimates increase by 31%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS and revenues miss analyst expectations

CEO & Director exercised options and sold US$111k worth of stock

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Lexicon Pharmaceuticals, Inc. Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

Price target decreased to US$8.00

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind